BUSINESS
Medicago’s COVID-19 Vaccine Shows Positive PI Results, Now Gearing Up for PII, PIII Studies
Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, said on November 10 that its investigational COVID-19 vaccine candidate (MT-2766) has demonstrated positive interim results in a PI clinical study carried out in Canada for the prevention of the disease. Medicago…
To read the full story
Related Article
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- FRONTEO Taps Bayer Ex-Chair Eiki as Advisor
July 22, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
- Carna Bio’s AML Drug Candidate Earns US Orphan Tag
July 22, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





